Cardiff Oncology Inc (NASDAQ: CRDF) stock closed at $3.52 on 5/3/24 after a major decline of -21.4%. NORMAL trading volume accompanied the decline. The stock has declined -11.8% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, CRDF is expected to continue to be Value Creation neutral.
Cardiff Oncology has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Cardiff Oncology has a very low Appreciation Score of 4 but a very high Power Rating of 99, and the Neutral Value Trend Rating results.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment